1 day Ago By ABMN Staff
Federated Hermes Inc. trimmed its holdings in LivaNova PLC ( NASDAQ:LIVN – Free Report ) by 4.4% in the second quarter, Holdings Channel reports.
The institutional investor owned 139,331 shares of the company’s stock after selling 6,364 shares during the period. Federated Hermes Inc.’s holdings in LivaNova were worth $7,638,000 at the end of the most recent reporting period.
A number of other hedge funds have also added to or reduced their stakes in the company. TradeLink Capital LLC bought a new position in LivaNova in the second quarter valued at approximately $208,000. Cornercap Investment Counsel Inc.
bought a new position in LivaNova in the second quarter valued at approximately $1,103,000. Texas Permanent School Fund Corp increased its stake in LivaNova by 4.1% in the second quarter.
Texas Permanent School Fund Corp now owns 49,086 shares of the company’s stock valued at $2,691,000 after acquiring an additional 1,939 shares during the last quarter. Great Lakes Advisors LLC bought a new position in LivaNova in the second quarter valued at approximately $16,614,000. Finally, Arizona State Retirement System increased its stake in LivaNova by 2.
0% in the second quarter. Arizona State Retirement System now owns 15,104 shares of the company’s stock valued at $828,000 after acquiring an additional 299 shares during the last quarter. 97.
64% of the stock is owned by institutional investors. LivaNova Stock Performance Shares of LivaNova stock opened at $51.00 on Wednesday.
The company has a quick ratio of 2.94, a current ratio of 3.45 and a debt-to-equity ratio of 0.
49. LivaNova PLC has a twelve month low of $42.75 and a twelve month high of $64.
47. The stock has a market cap of $2.77 billion, a price-to-earnings ratio of -85.
00 and a beta of 1.00. The company’s fifty day moving average is $48.
86 and its 200 day moving average is $53.44. Wall Street Analyst Weigh In A number of research analysts recently issued reports on the stock.
Stifel Nicolaus lifted their price objective on shares of LivaNova from $70.00 to $72.00 and gave the company a “buy” rating in a research note on Thursday, July 25th.
Robert W. Baird raised shares of LivaNova from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $55.00 to $66.
00 in a research note on Tuesday. Finally, Needham & Company LLC boosted their target price on shares of LivaNova from $72.00 to $75.
00 and gave the stock a “buy” rating in a research note on Wednesday, July 31st. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.
com, LivaNova currently has an average rating of “Moderate Buy” and a consensus target price of $70.80. Read Our Latest Stock Report on LIVN About LivaNova ( Free Report ) LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide.
The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. Read More Want to see what other hedge funds are holding LIVN? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for LivaNova PLC ( NASDAQ:LIVN – Free Report ). Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter .
.
